Alnylam announces results from HELIOS-B Phase 3 study of AMVUTTRA

Alnylam (ALNY) Pharmaceuticals announced results from new analyses of the HELIOS-B Phase 3 study of AMVUTTRA, an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, ATTR-CM, and the polyneuropathy of hereditary transthyretin-mediated amyloidosis, hATTR-PN, in adults. Data from a post hoc analysis of the HELIOS-B study, which assessed whether treatment with vutrisiran was associated with a reduction in gastrointestinal adverse events in patients with ATTR-CM, compared to placebo, were presented during a late-breaking session at the Heart Failure Society of America, HFSA, Annual Scientific Meeting 2025 in Minneapolis, Minnesota. The analysis showed that treatment with vutrisiran was associated with a lower rate of GI events across the overall, vutrisiran monotherapy, and baseline tafamidis treatment groups, compared to placebo, a trend that was consistent in patients living with both the wild-type and hereditary forms of the disease.